The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
Fenebrutinib targets cells in the immune system known as B cells and microglia
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
Subscribe To Our Newsletter & Stay Updated
